Bamco Inc. NY Has $119.87 Million Stake in Icon Plc $ICLR

Bamco Inc. NY reduced its stake in shares of Icon Plc (NASDAQ:ICLR) by 0.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 684,941 shares of the medical research company’s stock after selling 5,682 shares during the period. Bamco Inc. NY owned 0.85% of Icon worth $119,865,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Allworth Financial LP increased its holdings in shares of Icon by 64.4% during the 2nd quarter. Allworth Financial LP now owns 1,396 shares of the medical research company’s stock valued at $203,000 after acquiring an additional 547 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Icon by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 84,370 shares of the medical research company’s stock valued at $12,272,000 after acquiring an additional 2,159 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in Icon by 21.0% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,752,008 shares of the medical research company’s stock worth $545,730,000 after purchasing an additional 650,379 shares during the last quarter. SG Americas Securities LLC lifted its holdings in Icon by 12.3% in the 2nd quarter. SG Americas Securities LLC now owns 15,962 shares of the medical research company’s stock worth $2,322,000 after purchasing an additional 1,743 shares during the last quarter. Finally, Raiffeisen Bank International AG boosted its position in Icon by 7.1% during the second quarter. Raiffeisen Bank International AG now owns 7,500 shares of the medical research company’s stock worth $1,094,000 after purchasing an additional 500 shares during the period. Institutional investors own 95.61% of the company’s stock.

Icon Price Performance

NASDAQ:ICLR opened at $98.33 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. The firm has a market cap of $7.94 billion, a PE ratio of 13.31, a price-to-earnings-growth ratio of 2.52 and a beta of 1.35. Icon Plc has a 12 month low of $66.57 and a 12 month high of $211.00. The company’s 50-day moving average price is $144.09 and its two-hundred day moving average price is $165.46.

Analyst Ratings Changes

Several brokerages have commented on ICLR. Leerink Partners reiterated a “market perform” rating and set a $105.00 price target on shares of Icon in a report on Thursday, February 12th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Icon in a report on Monday, December 29th. Bank of America reiterated an “underperform” rating and issued a $75.00 target price on shares of Icon in a research note on Thursday, February 12th. BMO Capital Markets reiterated a “market perform” rating and issued a $100.00 target price on shares of Icon in a report on Thursday, February 12th. Finally, Robert W. Baird set a $119.00 target price on shares of Icon in a research report on Friday, February 13th. Six investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Icon currently has an average rating of “Hold” and an average target price of $146.80.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.